Price (delayed)
$11.12
Market cap
$463.56M
P/E Ratio
1.99
Dividend/share
N/A
EPS
$5.58
Enterprise value
$733.58M
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded
There are no recent dividends present for ICPT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.